Related Experiment Video
Updated: Jun 25, 2025
Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma
Published on: September 3, 2021
BMSC derived EVs inhibit colorectal Cancer progression by transporting MAGI2-AS3 or something similar
Tianyi Ma1, Meng Wang2, Song Wang3
1Department of Colorectal Surgery, the Second Affiliated Hospital of Harbin Medical University, Harbin 150000, China.
Abstract:
In this study, we investigated the molecular mechanisms underlying the impact of extracellular vesicles (EVs) derived from bone marrow stromal cells (BMSCs) on colorectal cancer (CRC) development. The focus was on the role of MAGI2-AS3, delivered by BMSC-EVs, in regulating USP6NL DNA methylation-mediated MYC protein translation modification to promote CDK2 downregulation. Utilizing bioinformatics analysis, we identified significant enrichment of MAGI2-AS3 related to copper-induced cell death in CRC. In vitro experiments demonstrated the downregulation of MAGI2-AS3 in CRC cells, and BMSC-EVs were found to deliver MAGI2-AS3 to inhibit CRC cell proliferation, migration, and invasion. Further exploration revealed that MAGI2-AS3 suppressed MYC protein translation modification by regulating USP6NL DNA methylation, leading to CDK2 downregulation and prevention of colorectal cancer. Overexpression of MYC reversed the functional effects of BMSC-EVs-MAGI2-AS3. In vivo experiments validated the inhibitory impact of BMSC-EVs-MAGI2-AS3 on CRC tumorigenicity by promoting CDK2 downregulation through USP6NL DNA methylation-mediated MYC protein translation modification. Overall, BMSC-EVs-MAGI2-AS3 may serve as a potential intervention to prevent CRC occurrence by modulating key molecular pathways.
Insights
Bone marrow stromal cell extracellular vesicles (EVs) deliver MAGI2-AS3 to inhibit colorectal cancer (CRC) by downregulating CDK2. This BMSC-EVs-MAGI2-AS3 therapy targets MYC translation, offering a potential CRC prevention strategy.
Area of Science:
- Molecular oncology
- Cell biology
- Cancer research
Background:
- Colorectal cancer (CRC) remains a significant health challenge.
- Extracellular vesicles (EVs) from bone marrow stromal cells (BMSCs) show therapeutic potential.
- Understanding the molecular cargo and mechanisms of BMSC-EVs in CRC is crucial.
Purpose of the Study:
- To elucidate the role of MAGI2-AS3, delivered by BMSC-EVs, in colorectal cancer progression.
- To investigate the molecular pathway involving USP6NL DNA methylation, MYC protein translation, and CDK2 regulation.
- To evaluate the therapeutic potential of BMSC-EVs carrying MAGI2-AS3 for CRC intervention.
Main Methods:
- Bioinformatics analysis to identify MAGI2-AS3 enrichment in CRC.
- In vitro studies using CRC cell lines to assess BMSC-EVs effects.
- Molecular assays to examine DNA methylation, protein translation, and gene expression.
- In vivo xenograft models to validate therapeutic efficacy.
Main Results:
- MAGI2-AS3 was downregulated in CRC cells and delivered by BMSC-EVs.
- BMSC-EVs-delivered MAGI2-AS3 inhibited CRC cell proliferation, migration, and invasion.
- MAGI2-AS3 suppressed MYC protein translation via USP6NL DNA methylation, leading to CDK2 downregulation.
- Overexpression of MYC counteracted the inhibitory effects of BMSC-EVs-MAGI2-AS3.
- In vivo studies confirmed BMSC-EVs-MAGI2-AS3's anti-tumorigenic activity.
Conclusions:
- BMSC-derived EVs deliver MAGI2-AS3, a key regulator in CRC.
- MAGI2-AS3 exerts anti-cancer effects by modulating USP6NL DNA methylation, MYC translation, and CDK2 levels.
- BMSC-EVs-MAGI2-AS3 represents a promising therapeutic strategy for colorectal cancer prevention.
More Related Videos
11:15A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
Published on: May 6, 2018
12:18LINE-1 Methylation Analysis in Mesenchymal Stem Cells Treated with Osteosarcoma-Derived Extracellular Vesicles
Published on: February 1, 2020
